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Abstract: T cell receptor activation of naïve CD8+ T lymphocytes initiates their maturation 
into effector cytotoxic T lymphocytes (CTLs) which can kill cancer and virally infected cells. 
Although CTLs show an increased reliance on glycolysis upon acquisition of effector function, 
we found an essential requirement for mitochondria in target cell killing. Acute mitochondrial 
depletion in USP30-deficient CTLs markedly diminished killing capacity although motility, 
signaling, and secretion were all intact. Unexpectedly, the mitochondrial requirement was 
linked to mitochondrial translation, inhibition of which impaired CTL killing. Impaired 
mitochondrial translation triggered attenuated cytosolic translation, precluded replenishment 
of secreted killing effectors, and reduced the capacity of CTLs to carry out sustained killing. 
Thus, mitochondria emerge as a previously unappreciated homeostatic regulator of protein 
translation required for serial CTL killing. 
One-Sentence Summary: Mitochondria are homeostatic regulators of serial killing by 
cytotoxic T lymphocytes. 
 
 
Main Text:  
 
CD8+ cytotoxic T lymphocytes (CTLs) are key players of the adaptive immune response. 
Activation of T cell receptors (TCRs) on naïve CD8+ T cells converts them into effector CTLs 
able to kill tumorigenic and virally infected cells. CTLs initiate cell death by secreting cytotoxic 
proteins, including perforin and granzymes, which selectively trigger caspase activation and 
subsequent apoptosis (1). An important attribute of CTLs is their ability to carry out “serial 
killing”, with a single CTL attacking multiple targets one after another, facilitating sustained 
killing (2-4). Thus, CTL function relies on motility to find and engage targets, TCR signaling 
for activation, and regulated secretion to effect killing.  
 Mitochondria play crucial roles in the adaptive immune system, mediating the 
development, metabolism, and activation of T cells (5-7). Although mitochondrial mass is 
correlated with CTL anti-tumor activity and increases after TCR-mediated activation (8-10), 
paradoxically CTLs show enhanced aerobic glycolysis (11, 12). How or why mitochondria 
impact target cell killing by differentiated CTLs is not well understood. 
 The removal of mitochondria by autophagy (mitophagy) is an important contributor to 
mitochondrial abundance and quality control (13, 14). The autophagic machinery can be 
recruited to mitochondria via a ubiquitin coat that forms in response to mitochondrial stress. 
Promiscuous ubiquitination is thought to be minimized by USP30, a transmembrane 
deubiquitinase (DUB) localized on the outer mitochondrial membrane (15-17). Thus, the loss 
of USP30-mediated deubiquitination results in increased mitophagy, thereby reducing cellular 
mitochondrial content.  
 A large-scale screen of single-gene deletion mice for immunological function identified 
USP30 as a regulator of CTL killing (18). T cell development was normal in Usp30−/− (KO) 
mice but CTLs generated after activation of naïve CD8+ T cells showed reduced killing of 
target cells. The role of USP30, and by inference mitochondria, in CTL function was intriguing 
because there is an increased reliance on glycolysis in activated effector T cells (11). These 
observations raised the possibility that mitochondria play a previously unappreciated role in 
CTL biology, and pointed to USP30 as a starting point for investigating this connection.  
 
Results 
Activation leads to an acute loss of mitochondria in USP30-deficient CD8+ T cells 
T cell development was unaffected in KO mice (18), with normal T cell populations in the 
spleen (fig. S1) that could then be used to generate CTLs, acquiring cytolytic activity 5-7 days 
after activation (Fig. 1A). Using tetramethylrhodamine ethyl ester (TMRE) (Fig. 1B) and 
MitoTracker Green (Fig. 1C) to label mitochondrial membrane potential and mass, 
respectively, we noted that WT and KO signals overlapped prior to activation (day 0). Upon 
activation, both WT and KO signals increased by day 3, consistent with an increase in 
mitochondria in activated T cells (9, 10).  However, by days 5-7, there was a loss of signal in 
KO but not WT CTLs, suggesting that mitochondria were selectively impacted in KO CTLs 
after TCR activation. Using immunofluorescence microscopy, we found that by day 5 after 
activation KO CTLs showed reduced levels of both the mitochondrial outer membrane protein 
TOM20 as well as the mitochondrial matrix enzyme pyruvate dehydrogenase (PDH) compared 
to WT CTLs (Fig. 1, D and E, and fig. S2). Using transmission electron microscopy (TEM), 
mitochondria in day 5 KO CTLs exhibited absent or disorganized cristae, with an empty 
appearance compared with mitochondria in WT CTLs (Fig. 1F), consistent with a role for 
USP30 in safeguarding the mitochondrial import protein TOM20 (19). Quantitation of TEM 
images demonstrated that 32% of KO CTLs showed disrupted mitochondrial morphology, 
whereas 60% lacked mitochondria completely. Only 8% of KO CTLs showed normal 
mitochondrial morphology compared with 73% of WT CTLs (Fig. 1G). Furthermore, the 
fluorescent, pH-dependent mitochondrial-Keima mitophagy reporter (mt-Keima) (20) revealed 
an increased mitophagic signal (red) in KO CTLs. Thus, TCR activation of CD8+ T cells 
lacking USP30 appeared to induce significant changes in mitochondrial number and 
morphology (Fig. 1, H and I, and movies S1 and S2). 
 Given the altered mitochondrial morphology, we asked whether mitochondrial function 
was affected. Oxidative phosphorylation was markedly reduced in day 5 KO CTLs, showing 
significant differences between both basal and maximal rates of respiration compared to WT 
CTLs (Fig 1J). Moreover, the decrease in oxygen consumption rate (OCR) was accompanied 
by an increase in extracellular acidification rate (ECAR), suggesting an even greater reliance 
on glycolysis in KO compared to WT CTLs (Fig. 1K). Thus, activation of CD8+ T cells lacking 
USP30 results in the generation of CTLs with significant changes in mitochondrial number and 
morphology, which are associated with impaired function. 
 
Mitochondrial depletion inhibits killing 
We found that day 5 KO CTLs exhibited a reduced killing capacity, particularly when required 
to kill for extended periods or when the number of CTLs was limiting. In a short-term killing 
assay, KO CTLs failed to kill targets until the ratio of CTL to targets was >7 and only killed 
40% of target cells when CTLs outnumbered targets by 25:1. By contrast, WT CTLs killed 
targets within 2.5 hours when the ratio of CTL to targets was >1 and killed all targets when 
CTLs outnumbered targets by 25:1 (Fig. 2A). Furthermore, a longer-term assay with 10 CTLs 
per target showed that KO CTLs took almost twice as long as WT CTLs to kill all targets (Fig. 
2B), demonstrating a reduced killing capacity in KO CTLs. Reducing the number of CTLs per 
target to 1:1 revealed similar levels of killing for WT and KO CTLs over the first 4 hours, after 
which KO CTLs showed no further killing, suggesting that KO CTLs lost the capacity to kill 
over time (Fig. 2C).   
 
ATP production, motility, signaling and secretion are unaffected by loss of mitochondria 
Mitochondria could contribute to many of the different steps required for killing as CTL seek, 
recognize, and kill their targets. Therefore, we sought to identify which were impacted in KO 
CTLs.  First we asked whether reduced oxidative phosphorylation affected killing by testing 
day 5 CTLs from Ndufs4−/− mice in which  complex I was disrupted (21). Despite a defect in 
maximal mitochondrial respiration, there was no defect in T cell development in Ndufs4−/−  
mice (fig. S3) or in CTL killing using either this genetic model, inhibitors of complex I, III, 
and V, or disruption of mitochondrial membrane potential (Fig. 2, D to F). As mitochondrial 
ATP has been shown to play a role in lymphocyte migration (22), we asked whether motility 
or ATP levels were affected in day 5 KO CTLs. We found no difference in motility (Fig. 3A 
and movies S3 and S4) nor overall ATP concentrations between WT and KO CTLs, with ATP 
concentrations reduced in both WT and KO upon selective inhibition of oxidative 
phosphorylation (oligomycin) or glycolysis (2-deoxy-D-glucose (2-DG)) (Fig. 3B). We found 
no defect in conjugate formation between day 5 KO CTLs and target cells or in polarization of 
the centrosome or cytolytic granules to the synapse formed between CTLs and targets (Fig. 3, 
C and D). Furthermore, day 5 KO CTLs showed no defects in either TCR-stimulated calcium 
fluxes nor the release of granules in response to TCR activation (Fig. 3, E and F).  Proximal 
and distal signaling events driven by TCR engagement also showed no difference between day 
5 WT and KO CTLs (fig. S4). Thus, ATP levels, motility, polarization, signaling, and secretion 
were all unaffected in KO CTLs. 
 
Mitochondrial depletion leads to translation attenuation and loss of cytolytic proteins 
Given that all steps to secretion appeared to be intact, we asked whether the secretory granules 
that store the cytolytic proteins required for killing were affected in day 5 KO CTLs. There 
were no gross changes in the morphology of KO compared to WT granules. However, we did 
note that although similar in number, the granules were smaller (quantitated by reduced surface 
area) in KO CTLs (Fig. 4, A to C). There was no evidence of granule autophagy, suggesting 
that the reduced size might rather reflect a reduction in granule content. Two of the key 
cytolytic proteins stored in granules are granzyme B and the pore-forming protein perforin (1). 
Granzyme B expression in KO CTLs was reduced relative to WT at days 5 and 7 after 
activation (Fig. 4D). Furthermore, although perforin was rapidly processed to its mature active 
form in WT CTLs, incompletely processed forms were evident in day 5 KO CTLs with a 
reduced level of mature perforin (Fig. 4E) (23). Notably, loss of protein was not due to changes 
in transcription, as mRNA expression was unchanged in day 5 KO relative to WT CTLs (Fig. 
4F), suggesting that a defect in protein synthesis may underlie the loss of cytolytic proteins in 
the KO.  
 Protein synthesis, monitored by incorporation of the methionine analogue 
homopropargylglycine (HPG) (24), was markedly reduced in day 5 KO CTLs relative to WT 
(Fig. 4G). Mimicking target encounter by cross-linking TCR (using anti-CD3ε) led to a modest 
increase in protein synthesis. This included renewed synthesis of granzyme B and perforin with 
newly synthesized intermediates of higher molecular weight (25), appearing in day 5 WT CTLs 
that could be abolished by treatment with the cytosolic protein synthesis inhibitor 
cycloheximide (CHX) (Fig. 4, H and I). By contrast, new synthesis was much reduced in the 
KO, suggesting that a defect in mRNA translation of cytolytic proteins might cause the loss of 
killing observed in KO CTLs.  To test this, we treated day 5 WT and KO CTLs with CHX in a 
long-term killing assay that required sustained killing. WT CTLs killed for the first 4 hours, 
after which CHX treatment reduced cytotoxicity, mirroring the pattern of killing by KO CTLs 
(Fig. 4J). In KO CTLs treated with CHX, target cell killing showed a further decrease between 
2-8 hours, consistent with the low levels of cytosolic protein synthesis observed.  Thus, de novo 
protein synthesis is required for sustained CTL killing and is impaired in KO CTLs. 
 
Cytolytic proteins are selectively impacted by the translational defect in USP30-deficient 
CTLs 
To determine whether the translational defect impacted all proteins equally, we used mass 
spectrometry to compare the proteomes of day 5 WT and KO CTLs before and after TCR 
activation.  Mass spectrometry data was normalized to the number of cells using a histone ruler 
approach in order to estimate protein mass and copy number per cell.  Analysis of these data 
not only confirmed the absence of USP30 (table S1), but also revealed that the decrease in 
protein synthesis did not affect the abundance of all proteins equally. Only a subset of proteins 
(557) was found to have a significantly lower expression in KO CTLs (fold change>2, 
FDR<10%) (Fig. 5A to C). Most affected were mitochondrial proteins (72%) (Fig. 5, B and C, 
and table S1), presumably reflecting their degradation by promiscuous mitophagy in the 
absence of USP30. Other highly downregulated proteins included granzyme B and 
eomesodermin, a transcription factor that regulates expression of cytotoxic proteins including 
perforin, granzyme B, and interferon gamma (IFN-γ) (26) (Fig. 5B and table S1).  A smaller 
number of proteins (35) were found to be significantly upregulated in KO CTLs (fold 
change>2, FDR<10%), including 11 proteins encoded from genes linked to the integrated stress 
response (Cebpb, Hmox1, Avil, Bcl2l11, Slca9, Niban1, Ifrd1, Cth, Bbc3, Ca2, and Plin2) and 
one involved in autophagy (p62/Sqstm1) (Fig. 5B and table S1).  Upon TCR activation of 
CTLs, additional cytolytic proteins were downregulated in KO CTLs (Fig. 5D and table S2), 
including IFNγ, TNFα, and TNFβ (Fig. 5E, fig. S5, and table S2). Thus, in addition to the loss 
of mitochondrial proteins, cytolytic proteins were particularly affected, decreasing the ability 
of KO CTLs to mount an effective response. Mitochondrial ribosomal proteins represented one 
of the most downregulated subsets within the mitochondrial compartment both before and after 
TCR stimulation (Fig. 5F). Cytosolic ribosomes were unaffected, indicating that the translation 
attenuation observed in the KO CTLs was not caused by a defect in cytosolic ribosomal content 
(Fig. 5G). Thus, mitochondria may be modulating the killing capacity of CTLs by regulating 
levels of cytolytic proteins.  
 
Mitochondrial translation is required for sustained CTL killing 
It is now well established that mitochondrial translation can regulate the synthesis of cytosolic 
proteins (27, 28). In addition, recent in vivo studies suggest roles for mitochondrial translation 
in T cell function (29, 30).  We therefore asked whether mitochondrial protein synthesis was 
disrupted in day 5 KO CTLs by examining HPG incorporation when cytosolic translation was 
inhibited by CHX (Fig. 6A) (31). Mitochondrial translation was evident in WT CTLs with HPG 
colocalizing with the mitochondrial marker, PDH. By contrast, there was little HPG 
incorporation in KO CTLs (Fig. 6A). To directly address the role of mitochondrial protein 
translation in CTL killing, we disrupted mitochondrial protein translation pharmacologically 
using doxycycline (DOX) (Fig. 6).  DOX treatment inhibited CTL cytotoxicity after 4 hours, 
which replicated the phenotype of KO CTL. There was a small additive effect of DOX 
treatment in KO CTLs, consistent with the inhibition of any remaining mitochondria in KO 
CTLs (Fig. 6B). Furthermore, cytosolic protein translation was inhibited after 1 hour of DOX 
treatment (Fig. 6C) and de novo synthesis of granzyme B and perforin after TCR activation (4 
hours) was also reduced (Fig. 6 D and E). These results were recapitulated with 
chloramphenicol inhibition of mitochondrial protein synthesis (fig. S6). Thus, the selective 
inhibition of mitochondrial translation is sufficient to attenuate selective cytosolic protein 
translation and to impair CTL cytotoxicity. 
 
Discussion 
Inhibition of mitochondrial translation is known to affect cytosolic translation via several 
pathways, including mTOR and the integrated stress response (ISR) (27, 28).  However, these 
pathways do not appear to be causative in the mitochondrial regulation of CTL killing. The 
mTOR target and ribosomal protein, S6, was phosphorylated in both KO and WT CTLs (fig. 
S4).   In addition, although we identified upregulation of some ISR proteins in KO CTLs, the 
ISR inhibitor (ISRIB) only partially restored protein synthesis and was unable to restore killing 
in KO CTLs (fig. S7). Two distinctive features of the KO CTLs were decreased oxidative 
phosphorylation (and increased reliance on glycolysis) (Fig. 1, J and K) together with 
selectivity in the downregulation of cytosolic protein synthesis (Fig. 5). Our proteomic analyses 
suggested an alternative mechanism that may contribute to the loss of killing when 
mitochondrial disruption triggers changes in metabolic pathways in the cell.  Many metabolic 
enzymes can “moonlight” as RNA-binding proteins (RBPs), which regulate the translation of 
selected mRNAs (32). The moonlighting functions of RBP metabolic enzymes can be induced 
by changes in CTL metabolism and can regulate expression of cytolytic proteins including 
granzyme B, TNFα, and IFNγ (33-35).  There was a selective downregulation of proteins in 
KO CTLs compared to CHX-treated CTLs (fig. S8A, and tables S1 and S3). Moreover, the 
expression of RBP enzymes was altered in both KO CTLs and CTLs where mitochondrial 
translation was inhibited (fig. S8, B to D, and tables S1 and S4). Using GO enrichment analysis, 
we noted 68% of commonly downregulated proteins in KO and DOX-treated CTLs were 
involved in cellular metabolism.  We propose that this metabolic re-wiring leads to the selective 
decrease in proteins required for sustained killing when mitochondrial translation is impaired. 
Our study highlights a role for mitochondria as homeostatic regulators of CTL killing.  
Early in an immune response antigen-specific CTLs will be limiting and the ability of 
individual CTLs to carry out sustained, serial killing will be critical to the success of the 
response.  Although previous studies have shown that the translational landscape of CD8+ T 
cells is especially active as they proliferate and acquire effector capacity (24), we now find that 
de novo protein synthesis is also required to sustain ongoing killing. Given the high energy 
demands required for protein synthesis (36), CTLs that need to continue killing have to rapidly 
rebalance their overall energy needs.  We find that this is mediated by mitochondria with the 
production of new cytolytic proteins synchronized with mitochondrial translation. In this way, 
mitochondria act as homeostatic regulators in times of high metabolic demand and serve a 





Materials and Methods  
(Reagents used in this study are listed in Table S5) 
Mice 
WT C57BL/6N and Usp30−/− (Usp30tm2b(EUCOMM)Hmgu) mice were bred and housed in the 
University of Cambridge Facility. This research has been regulated under the Animals 
(Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by 
the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). Age-
matched animals (male and female) of 8-20 weeks of age were used in experiments.  Spleens 
from Ndufs4−/−  mice were supplied by C.Viscomi and M. Zeviani (University of Padua) from 
mice at 4 weeks of age. 
Cell culture, and mitochondrial inhibitors 
Single-cell suspension of splenocytes, isolated using 70-µm cell strainers, were activated on 
plates coated with 0.5 μg/ml of anti-mouse CD3ε and 1 μg/ml of CD28 in CTL culture medium 
(RPMI 1640, 10% FBS, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml of penicillin, 1 
mg/ml of streptomycin, 50 µM β-mercaptoethanol, and 100 U/ml of mouse IL-2) for 48 hours 
at 37°C. After 72 hours CD8+ T cells were purified following manufacturer’s instructions for 
the CD8a+ T Cell Isolation Kit and cultured in CTL medium. P815 and P815-blue (37) target 
cells were grown in DMEM, 10% FBS, penicillin-streptomycin. P815-NucLight transduced 
cells (38) were maintained under 1 μg/ml puromycin selection.  
Mitochondrial translation was inhibited by supplementing the cell culture media with 10 μg/ml 
of doxycycline or 50-500 μg/ml of chloramphenicol throughout the killing (12 hours) and 
translation (1 hour) assays. CTLs used for immunoblots were treated with 10 μg/ml of 
doxycycline or 500 μg/ml of chloramphenicol for 4.5 hours before cell lysis. The integrated 
stress response was inhibited using 100 nM ISRIB throughout killing and translation assays. 
Mitochondrial respiration was inhibited in the Mito Stress (Seahorse) and killing (IncuCyte) 
assays using 1 μM FCCP, 1 μM oligomycin A, 0.5 μM rotenone, and 0.5 μM antimycin A. 
Killing assays 
CTLs (5 days after activation) were plated at the CTL-to-target ratios shown in phenol red-free 
RPMI 1640 (2% FBS, 1% penicillin, and streptomycin) in round-bottomed 96-well plates with 
104 P815 per well in the presence of 1 μg/ml of anti-mouse CD3ε. Cultures were then incubated 
at 37°C, 10% CO2 for 2.5 hours (short-term killing). The percentage of target cell lysis was 
determined using the CytoTox 96 assay following manufacturer’s instructions. 
Long-term killing assays were imaged in the IncuCyte S3 Live Cell Analysis System 
(Sartorius) that contains a Basler Ace 1920-155um compact camera and 4X objective, 
resolution 2.82 microns/pixel. CTLs (5 days after activation) were mixed with P815-NucLight 
targets in CTL culture medium with 1 μg/ml of anti-mouse CD3ε at the CTL-to-target ratios 
shown in ultra-low attachment round-bottomed 96-well plates (Corning, 7007). Plates were 
scanned using a 4X objective lens in both the brightfield and red (excitation: 655 nm; emission: 
681 nm) channels and analyzed using IncuCyte S3 v2018b software (Sartorius) to determine 
loss of target cells over time based on decrease of red fluorescence intensity. 
Granule release assay 
CTLs (5 days after activation) were incubated with anti-CD107a-PE (LAMP1) in CTL culture 
medium in the presence or absence of P815 target cells with 1 μg/ml of anti-mouse CD3ε for 
2.5 hours at 37°C, 10% CO2.  Cells were resuspended in ice-cold FACS buffer (PBS, 10% 
FBS), labeled for 20 min at 4°C with Brilliant Violet 711-conjugated anti-CD8 and Zombie 
Yellow, washed, and analyzed on an Attune NxT (ThermoFisher).  
Calcium flux assay 
CTLs (5 days after activation) were incubated with 1 μM INDO-1 for 30 min at 37°C, washed 
and incubated with 1 μg/ml of APC-conjugated anti-CD8 and 5 μg/ml of anti-CD3ε for 15 min 
at room temperature. CTLs were resuspended in T cell media and basal INDO-1 MFI was 
recorded for 1 min on an LSR Fortessa (Becton Dickinson). INDO-1 was excited at 355 nm 
and emission was collected at 450 nm (Ca2+-unbound) and at 379 nm (Ca2+-bound). TCR was 
crosslinked by addition of 50 μg/ml of goat anti-hamster antibodies and subsequent calcium 
fluxes were recorded for 5 min, after which 1 μg/ml of ionomycin was added to determine 
maximal calcium flux for 2 min. The MFI ratio of Ca2+-bound to Ca2+-unbound INDO-1 
(379/450) was calculated to display changes in intracellular calcium concentration. 
SDS-PAGE and immunoblotting 
Cells were lysed in RIPA buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, and 0.1% SDS) at 2×107 cells/ml. Lysates were resolved using 4 to 12% 
Bis-Tris or 7.5% SDS gels for perforin, before transfer to nitrocellulose filters. Membranes 
were blocked in 5% milk or 5% BSA (as indicated by antibody manufacturer) for 1 hour at 
room temperature before overnight incubation at 4°C with primary antibodies against β-actin, 
calnexin, granzyme B, perforin, TOM20, or phospho-S6 (Ser240/244). Membranes were 
washed in PBS, 0.1% Tween, incubated with goat anti-rabbit, mouse or rat HRP-conjugated 
antibodies for 1 hour in 5% milk or 5% BSA before washing and developing using ECL prime 
detection reagents (GE Healthcare, RPN2232) and imaged using a ChemiDoc MP Imaging 
System (Bio-Rad).  
RNA extraction and real-time qPCR 
Total RNA was extracted from CTLs (5 days after activation) using the RNeasy mini kit and 
QIAshredder columns and 100 ng per sample was used to synthesize cDNA using the 
Accuscript high fidelity first strand cDNA synthesis kit. Granzyme B and perforin gene 
expression were measured using the TaqMan Gene Expression Assay with qPCR probes for 
mouse transcripts of granzyme B, perforin, and TATA-binding protein (Tbp) as a control, using 
the 7500 Real-Time PCR System (ThermoFisher). mRNA abundance was quantified by 
calculating the CT of the target of interest and normalizing to Tbp (ΔCT). 
Measurement of mitochondrial mass and membrane potential 
Mouse CTLs were labeled with Zombie Yellow and Brilliant Violet 711-conjugated anti-CD8a 
for 15 min at room temperature, washed, and then incubated with 100 nM MitoTracker Green 
and 100 nM TMRE for 30 min at 37°C, 10% CO2. Samples were analyzed on day 0 (naïve T 
cells) and days 3, 5, and 7 post activation using an LSR Fortessa.  
Immunofluorescence imaging 
CTLs (5 days after activation) were washed in serum-free RPMI 1640 and allowed to adhere 
to slides at 37°C, 10% CO2 for 10 min before fixation with 5% paraformaldehyde (PFA) for 
15 min at 37°C and quenching in 50 mM ammonium chloride at room temperature. Cells were 
permeabilized for 10 min in either 0.1% Triton X-100 for PDH staining, or 0.1% saponin for 
TOM20 staining and blocked using PBS, 1% BSA for PDH staining, or 1% BSA, 0.1% saponin 
for TOM20 staining. Cells were labeled using anti-TOM20 or PDH for 2 hours washed in PBS, 
1% BSA (PDH) or PBS, 1% BSA, 0.1% saponin (TOM20), incubated with goat anti-mouse 
Alexa Fluor (AF) 546 for 1 hour, washed in PBS, Hoechst 33342 and mounted in ProLong 
Diamond. Samples were imaged using a Zeiss 63X 1.4NA PlanApochromat objective on a 
Zeiss LSM880 confocal microscope used in Airyscan mode and processed using Zen Black 
software (Zeiss). 
CTL-target conjugates were formed by mixing equal numbers of day 5 post-activation CTLs 
and P815-blue target cells in the presence of 1 μg/ml of anti-CD3ε for 20 min at 37°C, 10% 
CO2.  Cells were allowed to adhere on slides, fixed in ice-cold methanol for 5 min, blocked in 
PBS, 1% BSA and incubated with anti-γ-tubulin, anti-LAMP1 (supernatant, 1D4B), and Alexa 
Fluor 488-conjugated anti-CD8. After washing cells were labeled with Alexa Fluor 546-
conjugated anti-mouse IgG and Alexa Fluor 647-conjugated anti-rabbit IgG. Conjugate 
formation was imaged using an Andor Revolution spinning disk microscope with a Leica DMi8 
microscope, Yokogawa CSU-X1 spinning disk, Andor Technology iXon Ultra 888 EMCCD 
camera and Fusion software. Samples were imaged using an Olympus Plan Apochromat 100 
Å~ 1.4NA oil objective and z-step distances of 0.5 µm. 
Nucleofection with Lifeact-mApple and mt-Keima 
CTLs were nucleofected with 5 μg of plasmid DNA using P3 Primary cell nucleofector solution 
using the primary mouse T cell program of the 4D-Nucleofector system. Post-nucleofection, 
cells were incubated for at 37°C, 10% CO2 in mouse T Cell nucleofector medium with 10% 
FBS, 2 mM L-glutamine, and 0.01% DMSO. Cells were split after 4 hours into mouse T cell 
media and allowed to recover for at least 18 hours at 37°C, 10% CO2.  
Live-cell microscopy and quantification of cell migration and mitophagy 
CTLs (5 days post activation) were plated in dishes with a coverslip insert (pre-coated with 0.5 
μg/ml of ICAM-1/CD45 Fc) in CO2-independent media with 10% FBS and 2 mM L-glutamine, 
and imaged for 5 min at 37°C. All live microscopy samples were imaged on a Zeiss LSM 780 
with Zen Black software, using a Zeiss 63X 1.4NA PlanApochromat objective. Cell migration 
was quantified in CTLs (5 days after activation) expressing Lifeact-mApple, with nuclei 
stained with Hoechst, excited at 561 nm and 405 nm, respectively. The speed of CTL migration 
was quantified using the TrackMate plugin of ImageJ v1.52 (NIH), to track the motion of nuclei 
as an indicator of cell migration. Mitophagy was detected in CTLs expressing mt-Keima, 
excited at 488 nm (optimal excitation at pH=8) and 561 nm (optimal excitation at pH=4.5). 
The Imaris spot tracking function was used to filter the mt-Keima signal and calculate the mean 
fluorescence intensity (MFI) for each object. Spots were defined as “red” (mitolysosomes) 
when red MFI >2X green MFI. The percentage mitophagy was calculated from the number of 
red spots divided by the sum of green and red spots.  
Transmission electron microscopy 
CD8+ cells were purified using flow cytometry-based sorting 4 days post activation, using 
Zombie Aqua and APC-conjugated anti-CD8 and allowed to recover for up to 24 hours in CTL 
media at 37°C, 10% CO2.  CTL were washed and resuspended in serum-free RPMI, plated in 
four-well plastic tissue culture plates (Nunc) at 2×106 per sample and allowed to adhere at 37°C 
for 20 min. CTLs were fixed in 2% PFA/1.5% glutaraldehyde, washed and post-fixed in 1% 
osmium followed by 0.5% uranyl acetate, and processed for EPON embedding as described 
(39). Samples were from three independent biological replicates with two or more technical 
replicates analyzed per preparation. Sections (60-80 nm) were post-stained with lead citrate 
and viewed using a FEI Tecnai G2 Spirit BioTWIN transmission EM. Images were captured 
using a Gatan 4K US1000 CCD camera and FEI TIA software (v 4.7 SP3). For quantitation of 
mitochondria phenotype, images were collected of every cell profile within four (WT=128 cells 
total) or five (KO=154 cells total) grid squares of a single thin section (60-80 nm) of each of 
the WT and KO CTL samples. Each cell profile was scored for mitochondrial morphology as 
follows: none (no mitochondria), normal (normal mitochondria) and disrupted (mitochondria 
with disrupted cristae). For quantitation of lytic granule number and cross-sectional area, 
images were collected of every cell profile within four (WT=139 cells total) or five (KO=164 
cells total) grid squares of a single thin section for WT and KO CTL samples. Cross sectional 
area (nm2) was calculated using the lasso tool in Adobe Photoshop (CC 2019).  
Seahorse Mito Stress Assay 
Analysis of mitochondrial respiration and glycolytic rate of day 5 post-activation CTLs was 
performed using a Seahorse XFe96 extracellular flux analyzer with a Seahorse XF Cell Mito 
Stress Test Kit following manufacturer’s instructions. The Seahorse XFe96 FluxPak cartridge 
was hydrated with distilled water overnight at 37°C (no CO2) and equilibrated for 1 hour on 
the day of the assay in Seahorse XF Calibrant solution. Vessels were pre-coated with 22.4 
μg/ml of Cell-Tak for 20 min at 37°C to ensure continued adhesion of CTLs on the plate during 
the assay. DMEM used in the assay was supplemented with 10 mM glucose, 1 mM sodium 
pyruvate, and 2 mM L-glutamine, with pH adjusted to 7.4. To test the oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR), 1 μM oligomycin, 1 μM FCCP, and 
0.5 μM rotenone/antimycin A were loaded at the indicated times. Seahorse data were collected 
using Wave Controller 2.6 (Agilent). 
HPG protein synthesis assay 
Protein synthesis was assayed using the Click-iT HPG-AF488 Protein Synthesis Assay Kit. 
CTLs (5 days after activation) were washed and incubated for 30 min at 37°C in methionine-
free RPMI supplemented as for CTL culture medium. Protein synthesis was measured by 
addition of 100 μM Click-IT L-homoproparglycine (HPG) to the media. Cycloheximide (100 
μg/ml) was added to control samples to inhibit cytosolic translation. Cells were plated ±2 μg/ml 
of anti-CD3ε at 37°C, 10% CO2 for 1 hour to allow for HPG incorporation.  
Cells were then labeled with Zombie Violet and Brilliant Violet 711-conjugated anti-CD8 for 
20 min at 4°C. Samples were fixed in 3.7% PFA for 15 min at room temperature, washed in 
PBS, 3% BSA and permeabilized in PBS, 0.5% Triton X-100 and washed again in PBS, 3% 
BSA before HPG labeling through click-chemistry using azide-conjugated Alexa Fluor 488 
and washed in rinse buffer as indicated in manufacturer’s protocol. Cells were resuspended in 
PBS and analyzed on an Attune NxT. 
Mitochondrial protein synthesis was assayed by washing and incubating CTLs (5 days after 
activation) in T cell media using methionine-free RPMI and FBS dialysed against PBS (to 
remove methionine). After 30 min at 37°C in methionine-free media, 100 μg/ml of 
cycloheximide was added to inhibit cytosolic translation and 100 μM Click-IT L-
homoproparglycine (HPG) was added for 1-1.5 hours at 37°C, 10% CO2 to label protein 
synthesis in the mitochondria. CTLs were then washed in serum-free RPMI and allowed to 
adhere to slides at 37°C, 10% CO2 for 10-15 min before fixation with 3.7% PFA for 15 min at 
37°C. Cells were permeabilized for 20 min in 0.5% Triton X-100 and HPG was labeled through 
click-chemistry using azide-conjugated AF488. Samples were then washed in PBS and 
mitochondria were labeled using anti-PDH (2 hours) and anti-mouse-AF546 for 1 hour, at room 
temperature. Nuclei were stained using 200 ng/ml Hoechst 33342, mounted in ProLong 
Diamond and imaged using the Andor Revolution spinning disk microscope as described 
above. 
Intracellular cytokine staining 
WT and Usp30−/− CTLs (5 days after initial activation) incubated ±2 μg/ml of plate-bound anti-
CD3ε for 4.5 hours at 37°C, 10% CO2 were treated with GolgiStop (monensin), washed in PBS 
at 4°C, stained with Zombie Violet and Brilliant Violet 711-conjugated anti-CD8a for 20 min 
at 4°C, washed in PBS, 10% FBS and fixed and permeabilized using the Foxp3 Transcription 
Factor Staining Buffer following the manufacturer’s protocol and labeled with antibodies to 
IFNγ and TNFα for 30 min at room temperature. Cells were rinsed in permeabilization buffer 
and PBS, resuspended in PBS and analyzed using an Attune NxT. 
ATP assay 
ATP measurements were performed using the ATP Determination Kit. WT and Usp30−/− CTLs 
(5 days after activation) were incubated ±2 μg/ml of plate-bound anti-CD3ε for 4.5 hours at 
37°C, 10% CO2. Two million cells per sample were washed in PBS and lysed in distilled water 
by boiling at 90°C for 5 min as described before (40) before the supernatant was cleared by 
centrifugation at 18,800g for 10 min at 4°C. Control samples were treated with 25 μM 
oligomycin and 100 mM 2-deoxy-D-glucose (2-DG) to distinguish mitochondrial derived ATP 
from glycolysis-derived ATP, respectively, and lysed as above. ATP standards and ATP 
reaction buffer were prepared as indicated by manufacturer. The ATP concentration was 
quantified by measured by luminescence at 560 nm, using a SpectraMax M5 spectrophotometer 
and SoftMaxPro 5.4.1 (Molecular Devices). 
Cytof sample processing and analysis 
CTLs (5-7 days after activation) ±1 μg/ml of plate-bound CD3ε (145-2C11) for 1 hour at 37°C 
were stained using MaxPar reagent kits (Fluidigm) using metal-conjugated antibodies as 
described (41).  
Mass spectrometry processing and analysis 
CTLs (5 days after activation) were incubated ±2 μg/ml of plate-bound CD3ε (500A2) for 4.5 
hours at 37°C. Cytosolic translation was inhibited with 100 μg/ml of cycloheximide and 
mitochondrial translation with 10 μg/ml of doxycyline (DOX) for 4-4.5 hours.  Five million 
CTLs per sample were then washed twice in ice-cold PBS and flash-frozen on dry ice prior to 
processing for mass spectrometry. 
Protein lysates were generated from cell pellets as per (42) but using a lysis buffer of 5% SDS, 
50 mM TEAB pH 8.5, and 10 mM TCEP. Protein clean up and peptide generation was 
performed by the S-Trap method (43) as per manufacturer protocol (Protifi) and as previously 
described (44). 
For WT/KO and CHX-treated samples, 2 µg of peptide was analyzed per sample. Samples 
were injected onto a nanoscale C18 reverse-phase chromatography system (UltiMate 3000 
RSLC nano, ThermoFisher) then electrosprayed into an Q Exactive HF-X Mass Spectrometer 
(Thermo Scientific) as described in (44). Analysis for doxycycline-treated samples had the 
following differences: 1.5 µg peptide was injected per sample, analysis was performed on 
Orbitrap Exploris 480 Mass Spectrometer (ThermoFisher), sample were loaded at 10 μl/min 
onto trap column and the easy spray source operated in positive mode with spray voltage at 
2.445 kV, and the ion transfer tube temperature at 250°C. 
The data were processed, searched, and quantified with Spectronaut (45) 14 using the 
directDIA option using the same analysis settings as (44). The directDIA data were searched 
against a mouse hybrid database from databases in July 2019 Uniprot release described in (42).  
Protein copy number quantification was performed in the Perseus software package, version 
1.6.6.0. Mean copy number per cell was calculated using the “proteomic ruler” plugin as 
previously described (46). The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE (47) partner repository with the dataset 
identifiers PXD021508 (Usp30−/−, CHX) and PXD026948 (DOX). 
Flow cytometry and statistical analysis 
All flow cytometry data was acquired using the BD FACSDIVA (BD Biosciences) or Attune 
NxT software (ThermoFisher) and analyzed using FlowJo v10. Microscopy images were 
rendered and analyzed using Imaris 9 software (Bitplane).  Student’s t test was used to 
determine statistical significance as indicated in the figure legends. Graphs were generated 
using Prism 8 (GraphPad Software).  
For mass spectrometry data, copy number values were used to calculate fold change (FC). P-
values were calculated using a two-tailed paired Student’s t test and applying a false discovery 
rate (FDR) correction based on the Benjamini–Hochberg method. Analysis was performed in 
Microsoft Excel and RStudio. Copy number values were displayed as a heat map using 
Morpheus (Broad), whereas pie charts indicating cellular compartments were visualized using 
Prism 8 (GraphPad). Volcano plots were generated by plotting log2(FC) and log10(P) for all 
peptides on Tableau Interactive Dashboard 2020 and highlighting FDR based on the 
Benjamini–Hochberg method. 
Protein cellular localization was manually curated based on UniProt annotations 
(https://www.uniprot.org/). Mass contribution of proteins (grams per cell) was calculated as 
(protein copy number/cell) × (molecular weight (Daltons))/(Avogadro’s constant). The 
percentage of mitochondrial protein content of mitochondrial ribosomes was calculated by 
defining total mitochondrial proteins as the proteins from in the Mouse MitoCarta 2.0 database 
(48) and mitochondrial ribosomal proteins on the protein description terms “ribosomal protein” 
and “mitochondrial”. Cytosolic ribosomal proteins were defined by the KEGG term 
“ribosome”. Moonlighting metabolic enzymes were based on their RNA-binding protein 
(RBP) ability, as previously reported (32, 33, 49-51). For gene ontology (GO) enrichment 
analysis, values for FC and FDR correction were compared for proteins detected in the mass 
spectrometry of both KO vs WT and DOX-treated vs untreated CTLs (all unstimulated). 
Proteins with corrected P-values below the 10% FDR statistical threshold were selected for 
further analysis. GO enrichment (http://geneontology.org/) (52, 53) was analyzed by detecting 
overrepresented “biological process” in the list of commonly downregulated proteins in KO 
and DOX-treated CTLs. 
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Fig. 1. Usp30 deletion leads to mitochondrial depletion in effector CD8+ T cells. 
(A) Isolation and stimulation of murine primary CD8+ T cells. (B and C) Time course of 
mitochondria labeled with (B) TMRE and (C) MitoTracker Green in WT and Usp30−/− naïve 
CD8+ T cells (day 0) as they mature into CTLs after stimulation (day 3-7). Immunofluorescence 
staining of (D) TOM20 (outer mitochondrial membrane) and (E) PDH (mitochondrial matrix) 
in day 5 WT and Usp30−/− (KO) CTLs. Scale bars=10 μm. (F) Transmission electron 
microscopy (TEM) sections (70 nm) of mitochondria in day 5 WT and Usp30−/− (KO) CTLs, 
scale bars=500 nm, and (G) quantitation of TEM images from 128 WT and 154 KO cell 
profiles. (H) Quantitation of live cell imaging of day 5 WT and Usp30−/− (KO) CTLs 
expressing mt-Keima. Each data point shows percentage of mitolysosomes (red mt-Keima 
signal) in a 63X field, indicative of mitophagy (>40 cells per genotype in each independent 
repeat). (I) Representative images of mt-Keima signal in day 5 WT and Usp30−/− (KO) CTLs. 
Scale bars=15 μm. (J) Mitochondrial respiratory capacity indicated by oxygen consumption 
rate (OCR) in day 5 WT and Usp30−/− (KO) CTLs. (K) Basal glycolysis in day 5 WT and 
Usp30−/− (KO) CTLs measured by extracellular acidification rate (ECAR) values at resting 
state. **=P<0.01, ***=P<0.001 (two-tailed unpaired Student’s t test). Error bars show mean 
values ±SD of technical replicates in one representative experiment. All data are representative 




Fig. 2. Mitochondrial depletion leads to OXPHOS-independent inhibition of killing. 
(A) Short-term (2.5 hours) killing assay with day 5 WT and Usp30−/− (KO) CTLs, varying 
CTL-to-target ratio. (B) Long-term (10 hours) killing assay showing percentage of target cell 
lysis over time (CTL-to-target ratio, 10:1) with day 5 WT and Usp30−/− (KO) CTLs. (C) Long-
term (12 hours) killing assay showing percentage of target cell lysis over time (CTL-to-target 
ratio, 1:1) with day 5 WT and Usp30−/− (KO) CTLs. (D) Long-term (10 hours) killing assay 
showing percentage of target cell lysis over time (CTL-to-target ratio, 10:1) with day 5 WT 
and Ndusf4−/− CTLs. (E) Mitochondrial respiratory capacity shown by oxygen consumption 
rate (OCR) in day 5 WT and Ndufs4−/− CTLs. (F) Long-term (12 hours) killing assay showing 
percentage of target cell lysis over time (CTL-to-target ratio, 1:1) with day 5 WT CTL treated 
with inhibitors used in the Seahorse assay: Complex I (rotenone), III (antimycin A), V 
(oligomycin), and the uncoupling reagent, FCCP. Errors bars in show mean values ±SD of (A 
to C and F) technical replicates, (D and E) biological replicates. All data are representative of 
at least two independent biological replicates. 
  
 
Fig. 3. Loss of USP30 does not impair ATP production, migration, target recognition or 
secretion. 
(A) Track speed analysis of migrating day 5 WT and Usp30−/− (KO) CTLs (>200 cells per 
genotype per repeat; solid lines, median; dotted lines, quartiles). (B) ATP quantitation in day 5 
WT and Usp30−/− (KO) CTLs, with (anti-CD3) or without (basal) TCR activation or treated 
with oligomycin and/or 2-deoxy-D-glucose (2-DG) to account for mitochondria-derived and 
glycolysis-derived ATP respectively. (C) Quantitation of conjugate formation between day 5 
WT and Usp30−/− (KO) CTLs and P815 target cells (>70 cells per genotype per independent 
repeat). Each dot shows the average percentage of conjugates in a 63X field. (D) Conjugates 
formed by day 5 WT or Usp30−/− (KO) CTLs (green) with P815 targets (blue) showing 
polarization of cytolytic granules (red) and centrosome (white). Scale bars=5 μm. (E) INDO-1 
calcium assay showing changes in intracellular calcium concentration in day 5 WT and 
Usp30−/− (KO) CTLs before (t=0-60 s) and after TCR crosslinking (t=60 s) or ionomycin 
addition (t=300 s). (F) Histograms representing surface LAMP1-PE fluorescence intensity in 
day 5 WT and Usp30−/− (KO) CTLs before and after incubation with P815 target cells. 
a.u.=arbitrary unit. ns=not significant, **=P<0.01, ***=P<0.001 (unpaired two-tailed 
Student’s t test). All error bars show mean values ±SD of technical replicates. Data are 




Fig. 4. Mitochondrial depletion leads to translation attenuation and reduced expression 
of key cytolytic proteins. 
(A) TEM sections (70 nm) of lytic granules in day 5 WT and Usp30−/− (KO) CTLs, scale 
bar=500 nm, and quantitation of (B) cross-sectional surface areas, and (C) lytic granule number 
(solid line, median; dotted lines, quartiles) from 139 (WT) and 164 (KO) profiles. 
***=P<0.001 (two-tailed unpaired Student’s t test). Immunoblots showing (D) granzyme B 
(GzmB) and (E) perforin (Prf1) in WT and KO CTLs. Immature (1), intermediate (2), and 
mature (3) forms of perforin are labeled. (F) Granzyme B (GzmB) and perforin (Prf1) mRNA 
in day 5 WT and KO CTLs; ΔCT normalized to TATA-binding protein mRNA (Tbp). Error 
bars show mean values ±SD of three biological replicates. ns=not significant (two-tailed paired 
Student’s t test). (G) HPG-AF488 incorporation (1 hour) into day 5 WT and Usp30−/− (KO) 
CTLs, ± anti-CD3 (TCR activation) where shown, or cycloheximide (CHX)-treated CTLs in 
which cytosolic translation is inhibited (control). Immunoblots showing (H) granzyme B 
(GzmB) and (I) perforin (Prf1) in day 5 WT and Usp30−/− (KO) CTLs ±anti-CD3 or CHX. 
Newly synthesized GzmB indicated by (*). (J) Long-term (12 hours) killing assay with day 5 
WT and Usp30−/− (KO) CTLs (CTL-to-target, 1:1), ±CHX. Error bars show mean values ±SD 
of technical replicates in one representative experiment. All data are representative of at least 





Fig. 5. Proteomic analysis of mitochondrially depleted Usp30−/− CTLs. 
(A) Heat map showing global protein expression (protein copy number) in day 5 WT and 
Usp30−/− (KO) CTLs. (B) Volcano plot of upregulated (right quadrant) and downregulated (left 
quadrant) proteins in day 5 Usp30−/− (KO) CTLs compared to WT. Vertical bars denote 
log2(FC)=1,-1 and horizontal bar corresponds to the uncorrected P=0.05 threshold. Colored 
dots show hits within the 5% and 10% false discovery rate (FDR) range. GOCC-defined 
mitochondrial proteins are highlighted according to FDR. (C) Cellular localization of 
downregulated proteins in day 5 Usp30−/− (KO) CTLs (5% FDR). (D) Heat map displaying 
global protein expression (protein copy number) in anti-CD3-stimulated (TCR activated, 4.5 
hours) day 5 WT and Usp30−/− (KO) CTLs. (E) Volcano plot of upregulated and 
downregulated proteins in anti-CD3-stimulated day 5 Usp30−/− (KO) CTLs compared to WT. 
Quadrants and color scheme as in (B). Highlighted proteins are referenced by gene names in 
(B) and (E). (F) Percentage of mitochondrial ribosomal protein out of total mitochondrial 
peptides detected in unstimulated, anti-CD3 and CHX-treated day 5 CTLs. (G) Cytosolic 
ribosome protein expression in unstimulated, anti-CD3 and CHX-treated day 5 CTLs. Error 
bars show mean values ±SD from biological replicates (F and G). All data are representative 
of four biological replicates.  
  
 
Fig. 6. Mitochondrial translation is required for sustained T cell killing. 
(A) Immunofluorescence imaging of mitochondrial translation using 1-hour HPG-AF488 
incorporation into day 5 WT and Usp30−/− (KO) CTLs treated with cycloheximide (CHX) to 
inhibit cytosolic translation. CTLs were either left untreated or treated with 10 μg/ml of 
doxycycline (DOX) to selectively inhibit mitochondrial translation as indicated. Scale bars=7 
μm. (B) Long-term (12 hours) killing assay (CTL-to-target ratio, 1:1) showing percentage 
target lysis with day 5 WT and KO CTLs treated with DOX. Error bars show mean values ±SD 
of technical replicates. (C) HPG-AF488 incorporation into day 5 WT CTLs treated for 1 hour 
with DOX to inhibit mitochondrial translation or CHX to inhibit cytosolic translation (control), 
stimulated with anti-CD3 (TCR) where shown. Immunoblots showing (D) Granzyme B 
(GzmB) and (E) perforin (Prf1) in day 5 WT CTLs treated with DOX and/or stimulated via 
TCR activation (anti-CD3) as indicated for 4 hours. Newly synthesized granzyme B indicated 
by (*). Immature (1), intermediate (2), and mature (3) forms of perforin are indicated. Error 
bars show mean values ±SD of technical replicates in one representative experiment. All data 
are representative of at least three independent biological replicates.  
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Fig. S1. Analysis of WT and Usp30-/- splenocytes. 
(A) CD4+/CD8+ ratio in WT and Usp30–/– (KO) splenocytes. (B) CD4+ and CD8+ naïve 
(CD62Lhi, CD44lo), central memory (CD62Lhi, CD44hi) and effector memory (CD62Llo, 
CD44hi) T cell subsets in WT and Usp30–/– (KO) splenocytes. (C) Regulatory T cells (CD4+, 
Foxp3+) in WT and Usp30–/– (KO) splenocytes. (D to H) Quantitation of (D) CD4+, (E) 
regulatory T cells, (F) CD8+, (G) total CD4+ and (H) CD8+ subsets (naïve, central memory, 
and effector memory). Plots show the average of three biological replicates ±SD. ns=not 





Fig. S2. TOM20 and PDH expression in WT and Usp30-/- CTLs. 
(A to B) Quantitation of day 5 CTLs expressing (A) TOM20 and (B) TOM20 MFI by 
immunofluorescence (>65 cells per genotype in each independent repeat). (C) Immunoblot 
showing TOM20 protein expression in day 5 WT and Usp30–/– (KO) CTLs. (D to E) 
Quantitation of day 5 CTLs expressing (D) PDH and (E) PDH MFI by immunofluorescence 
(>60 cells per genotype in each repeat). Error bars (A, D) show mean values ±SD of technical 
replicates in one representative experiment. ***=P<0.001 (two-tailed unpaired Student’s t 
test). Dashed lines, median; dotted lines, quartiles in (B, E). All data representative of at least 






Fig. S3. Analysis of OXPHOS deficiency in splenocytes and CTL killing. 
(A to C) WT and Ndufs4–/– splenocytes: (A) CD4+/CD8+ ratio, (B) CD4+ and CD8+ naïve 
(CD62Lhi, CD44lo), central memory (CD62Lhi, CD44hi) and effector memory (CD62Llo, 
CD44hi) T cell subsets, (C) regulatory T cells (CD4+, Foxp3+). (D to H) Quantitation of (D) 
CD4+, (E) CD8+, (F) regulatory T cells, (G) CD4+ subsets and (H) CD8+ subsets (naïve, central 
memory, and effector memory). Plots show the average of three biological replicates ±SD. ns= 
not significant (two-tailed paired Student’s t test).  
 
 
Fig. S4. Proximal and distal TCR signaling is not affected by mitochondrial depletion. 
(A to I) TCR signal transduction in anti-CD3-stimulated WT and Usp30–/– (KO) CTLs (TCR 
activated, 1 hour). Phosphorylation of distal and proximal markers was measured via mass 
cytometry (CyTOF). Histograms showing fluorescence intensity for (A) pZAP70, (B) pSLP76, 
(C) pPLCγ1, (D) pLCK, (E) pERK1/2, (F) pAKT, (G) pSTAT5, (H) pIκBα, and (I) pS6. (J) 
Immunoblot showing phosphorylation of the mTOR target S6 in day 5 WT and Usp30–/– (KO) 
CTLs with TCR activation via anti-CD3 stimulation (4.5 hours), and/or cytosolic protein 
synthesis inhibited by cycloheximide (CHX). S6 phosphorylation increases in both WT and 
Usp30–/– (KO) CTLs upon TCR stimulation. Data representative of at least two independent 




Fig. S5. Cytokine production is impaired in mitochondria-depleted CTLs. 
 
IFNγ (A) and TNFα (B) cytokine production in day 5 WT and Usp30–/– (KO) CTLs before and 
after 4.5 hours anti-CD3 stimulation (TCR activation). Data representative of at least three 
independent biological replicates.  
 
Fig. S6. Chloramphenicol treatment inhibits mitochondrial translation and T cell killing. 
(A) Mitochondrial translation visualized by HPG-AF488 incorporation (green) into 
mitochondria (PDH, red) in day 5 WT and Usp30–/– (KO) CTLs treated with cycloheximide (to 
inhibit cytosolic translation). CTLs were treated where indicated with chloramphenicol (CAM) 
an inhibitor of mitochondrial translation. Scale bars=10 μm. (B) Long-term (12 hours) killing 
assay using day 5 WT CTLs (CTL-to-target ratio, 1:1) showing percentage target lysis with 
increasing concentrations of CAM. Error bars show mean values ±SD of technical replicates 
in one representative experiment. (C) HPG-AF488 incorporation into day 5 WT CTLs treated 
for 1 hour with chloramphenicol (CAM) to inhibit mitochondrial translation or CHX to inhibit 
cytosolic translation (control), stimulated with anti-CD3 (TCR) where shown. Immunoblots 
showing (D) granzyme B (GzmB) and (E) perforin (Prf1) in day 5 WT CTLs treated with 
chloramphenicol (CAM), and/or stimulated via TCR activation (anti-CD3) as indicated for 4 
hours. Newly synthesized granzyme B indicated by (*). Immature (1), intermediate (2), and 




Fig. S7. ISR inhibition is not sufficient to restore translation nor cytotoxicity in Usp30–/–
CTLs. 
(A) Volcano plot of upregulated proteins in day 5 Usp30–/– (KO) CTLs compared to WT. 
Vertical bar denotes log2(FC)=1 and horizontal bar corresponds to the uncorrected P=0.05 
threshold. Colored dots show hits within the 5% and 10% false discovery rate (FDR) range. 
GOCC-defined mitochondrial proteins are highlighted according to FDR. Proteins indicating 
upregulation of the integrated stress response (ISR) are labeled by gene name. (B) HPG-AF488 
incorporation in day 5 WT and Usp30–/– (KO) CTLs treated with 100 nM ISR inhibitor (ISRIB) 
(1 hour). TCR activated via anti-CD3 stimulation. Control sample was treated with 
cycloheximide (CHX) to inhibit cytosolic protein synthesis. (C) Long-term killing assay (CTL 
to target ratio, 1:1) showing percentage of target lysis with day 5 WT and Usp30–/– CTLs treated 
with 100 nM ISR inhibitor (ISRIB). Error bars show mean values ±SD of technical replicates 




Fig. S8. RNA-binding metabolic enzymes show altered expression in Usp30–/– (KO) and 
doxycycline-treated CTLs. 
(A) Proteomes of stimulated (4 hours anti-CD3) day 5 CTLs from Usp30–/– (KO) CTLs 
compared with WT CTLs, and WT CTLs in which cytosolic protein synthesis was inhibited by 
CHX compared with untreated CTLs.  Comparison of effect sizes emphasizes a selective 
downregulation of protein synthesis in KO CTLs, with only partial overlap with effects of CHX 
treatment. Dotted lines correspond to log2(FC)=0. Colored dots show proteins within the 10% 
false discovery rate (FDR) in the Usp30–/– (KO) vs WT dataset (light blue) and in the CHX vs 
untreated dataset (green). Magenta-labeled dots indicate proteins within the 10% FDR common 
to both datasets. (B-C) Volcano plots of downregulated proteins in (B) unstimulated, and (C) 
TCR-activated day 5 Usp30–/– (KO) CTLs compared to day 5 WT. Colored dots show 
metabolic enzymes moonlighting as RNA-binding proteins (RBP) within the 5% (red) and 10% 
(blue) FDR range. (D) Volcano plot of downregulated proteins in day 5 CTLs after short-term 
(4 hours) treatment with doxycycline. Colored dots show enzymes moonlighting as RBP within 
the 10% FDR range (blue) and RBP enzymes within the 10% FDR showing downregulated 
expression in both Usp30–/– (KO) and doxycycline-treated CTLs (orange). Non-significant 
(n.s.) RBPs are colored in light green in (C, D). Highlighted proteins referred to by gene name 
in (D). Horizontal bar: uncorrected P=0.05. All data representative of four independent 
biological replicates. 
  
Table S1. Mass spectrometry of WT and KO CTLs (separate file) 
Proteomics data including gene and protein name, protein description, 
GOBP/GOMF/GOCC/KEGG terms, mean protein copy number, fold change (FC), p-value 
(two-tailed paired Student’s t test) and false discovery rate (FDR, Benjamini–Hochberg 
method) for day 5 WT and Usp30–/– (KO) CTLs. 
Table S2. Mass spectrometry of TCR-stimulated WT and KO CTLs (separate file) 
Proteomics data including gene and protein name, protein description, 
GOBP/GOMF/GOCC/KEGG terms, mean protein copy number, fold change (FC), P-value 
(two-tailed paired Student’s t test) and false discovery rate (FDR, Benjamini–Hochberg 
method) for day 5 WT and Usp30–/– (KO) CTLs after 4.5 hours of anti-CD3-mediated 
stimulation mimicking TCR activation. 
Table S3. Mass spectrometry of TCR-stimulated, CHX-treated WT CTLs (separate file) 
Proteomics data including gene and protein name, protein description, 
GOBP/GOMF/GOCC/KEGG terms, mean protein copy number, fold change (FC), p-value 
(two-tailed paired Student’s t test) and false discovery rate (FDR, Benjamini–Hochberg 
method) for WT CTLs after 4.5 hours of anti-CD3-mediated stimulation mimicking TCR 
activation. Day 5 CTLs were either left untreated (“WT stimulated”) or treated with 100 μg/ml 
cycloheximide (“WT stimulated + CHX”) (4.5 hours). 
Table S4. Mass spectrometry of DOX-treated WT CTLs (separate file) 
Proteomics data including gene and protein name, protein description, 
GOBP/GOMF/GOCC/KEGG terms, mean protein copy number, fold change (FC), P-value 
(two-tailed paired Student’s t test) and false discovery rate (FDR, Benjamini–Hochberg 
method) for day 5 WT CTLs either left untreated (“WT untreated”) or treated with 10 μg/ml 
doxycycline (“WT + DOX”) (4 hours). 
Table S5. Table of reagents (see below) 
Movie S1. Mitophagy in WT CTLs (separate file) 
mt-Keima signal in day 5 WT CTLs migrating on ICAM-1-coated dishes. Green=mitochondria 
(excitation=488nm); red=mitolysosomes (excitation=561 nm). CTLs imaged for 5 min at 37ºC 
using a 63 X objective. 
Movie S2. Mitophagy in KO CTLs (separate file) 
mt-Keima signal in day 5 Usp30–/– (KO) CTLs migrating on ICAM-1-coated dishes. 
Green=mitochondria (excitation=488nm); red=mitolysosomes (excitation=561nm). CTLs 
imaged for 5 min at 37ºC using a 63 X objective. 
Movie S3. WT CTL migration (separate file) 
Migration of day 5 WT CTLs on ICAM-1-coated dishes. CTLs nucleofected with Lifeact-
mApple to visualize F-actin and stained with Hoechst to label nuclei. CTLs imaged for min at 
37ºC using a 63 X objective. 
Movie S4. KO CTL migration (separate file) 
Migration of day 5 Usp30–/– (KO) CTLs on ICAM-1-coated dishes. CTLs nucleofected with 
Lifeact-mApple to visualize F-actin and stained with Hoechst to label nuclei. CTLs imaged for 
5 min at 37ºC using a 63 X objective. 
 




Host Clone Fluor Company Cat #  RRID Final conc. 
/dilution 
Mouse CD3 Hamster 500A2 none ThermoFisher 16-0033 AB_842782 0.5-2 μg/ml 
Mouse CD3 Hamster 145-2C11 none BDBiosciences 553058 AB-394591 1 μg/ml 
Mouse CD28 Hamster 37.51 none ThermoFisher 16-0281 AB_468921 1 μg/ml 
Mouse CD8a Rat 53-6.7 BV711 Biolegend 100747 AB_2562100 1 μg/ml (Facs) 
Mouse CD8a Rat 53-6.7 APC Biolegend 100712 AB_312751 1 μg/ml (Facs) 
Mouse CD8a Rat 53-6.7 AF488 ThermoFisher 53-0081 AB_469896 5 μg/ml (IF) 
Mouse LAMP1 Rat 1D4B PE ThermoFisher 12-1071 AB_657555 2 μg/ml (Facs) 
Mouse LAMP1 Rat 1DB4 none DSHB 1DB4 AB_2134500 1:2 (IF) 
γ-tubulin Rabbit polyclonal none Sigma T5192 AB_261690 1:1000 
β-actin Mouse AC-15 none Sigma A1978 AB_476744 1:5000 
Calnexin Rabbit Polyclonal none Sigma C4731 AB_476845 1:5000 
Granzyme B Rabbit Polyclonal none Abcam ab4059 AB_304251 1:500 
Mouse perforin Rat CB5.4 none Enzo  ALX-804057 AB_2052202 1:500 
TOM20 Mouse 4F3 none Abcam ab56783 AB_945896 4 μg/ml (WB) 
10 μg/ml (IF) 
PDH Mouse 9H9AF5 none Abcam ab110330 AB_10858459 1 μg/ml (IF) 
pS6 (S240/244) Rabbit D68F8 none Cell Signaling  5364S AB_10694233 1:500  
Mouse IFNγ Rat XMG1.2 PE BioLegend 505808 AB_315402 1 μg/ml 
Mouse TNFα Rat MP6XT22 AF488 BioLegend 506313 AB_493328 1 μg/ml 
Rabbit IgG Goat polyclonal HRP ThermoFisher A16110 AB_2534782 1:10,000 
Mouse IgG Goat polyclonal HRP ThermoFisher A16078 AB_2534751 1:10,000 
Rat IgG Goat polyclonal HRP ThermoFisher 31470 AB_228356 1:10,000 
Mouse IgG Goat polyclonal AF546 ThermoFisher A-11030 AB_144695 5 μg/ml (IF) 
Rabbit IgG Donkey polyclonal AF647 ThermoFisher A-31573 AB_2536183 5 μg/ml (IF) 
Hamster IgG Goat polyclonal none ThermoFisher 31115 AB_394591 50 μg/ml (Facs) 
 
Dyes 
Reagent Supplier Cat # Final conc 
Hoechst 33342 ThermoFisher H3570 1:50,000 
Zombie Yellow (Viability) BioLegend 423103 1:400 
Zombie Violet (Viability) BioLegend 423114 1:400 
Zombie Aqua BioLegend 423102 1:400 
MitoTracker Green ThermoFisher M7514 100 nM 
TMRE Abcam ab113852 100 nM 
INDO-1 ThermoFisher I1223 1 μM 
 
 
Media and cell culture 
Reagent Supplier Cat # Final conc 
RPMI 1640 ThermoFisher 21875  
DMEM ThermoFisher 41966  
RPMI no methionine ThermoFisher A1451701  
CO2-independent media ThermoFisher 18045-054  
Phenol red free RPMI Gibco 32404-014  
L-Glutamine Sigma G7513 2 mM 
Sodium pyruvate Sigma 11360070 1 mM 
Penicillin &  
Streptomycin 
ThermoFisher P0781 100 U/ml & 
1 mg/ml 
β-mercaptoethanol ThermoFisher 31350010 50 μM 
Foetal bovine serum (FBS) LabTech, FBS-Sa  10% 
Recombinant murine IL-2 Peprotech 212-12 100 U/ml 
Puromycin (selection) ThermoFisher A11138 1 μg/ml 
 
Mice 
Strain Background Supplier RRID 
C57/BL6N/WTSI (WT) C57/BL6N Wellcome Trust Sanger Institute SCR_006158 
C57BL/6N-Usp30tm2b(EUCOMM)Hmgu/Wtsi C57/BL6N Wellcome Trust Sanger Institute IMSR_EM:09833 
 
Cell lines  
Cell line Species/origin Supplier RRID 
P815 Mouse mastocytoma Basel Institute for Immunology CVCL_2154 
 
Inhibitors 
Reagent Supplier Cat # Final conc 
Doxycycline Merck D9891 10 μg/ml 
Chloramphenicol Sigma R4408 50-500 μg/ml 
ISRIB Sigma SML0843 100 nM 
FCCP Sigma C2920 1 M 
Oligomycin Sigma 75351 1 M 
Rotenone Sigma R8875 0.5 M 
Antimycin A Sigma A8674 0.5 M 
Cycloheximide Sigma C4859 100 μg/ml 
 
CD8+ isolation and Nucleofection reagents 
Reagent Supplier Cat # 
CD8a+ T Cell Isolation Kit Miltenyi 130-104-075 
P3 Primary Cell Nucleofector Kit Lonza V4XP-3024 
Mouse T Cell Nucleofector Kit Lonza VZB-1001 
 
qPCR reagents 
Reagent Supplier Cat # 
RNeasy mini kit Qiagen 74104 
QIAshredder columns Qiagen 79654 
Accuscript cDNA synthesis kit Agilent 200820 
TaqMan gene expression mastermix ThermoFisher 4369016 
TaqMan gene expression assay ThermoFisher 4331182 
Mouse granzyme B qPCR probe ThermoFisher Mm00442837_m1 
Mouse perforin qPCR probe ThermoFisher Mm00812512_m1 
Mouse TATA-binding protein (Tbp) qPCR probe ThermoFisher Mm01277042_m1 
 
 
HPG protein synthesis reagents 
Reagent Supplier Cat # 
Click-iT HPG Alexa Fluor 488 Protein Synthesis Assay ThermoFisher C10428 
Click-IT L-homoproparglycine (HPG) ThermoFisher C10186 
 
Seahorse reagents 
Reagent Supplier Cat # 
Seahorse XF Cell Mito Stress Test Kit Agilent 103015-100 
Seahorse XFe96 FluxPak cartridge Agilent 102416-100 
Seahorse XF Calibrant solution Agilent 103059-000 
Cell-Tak Corning 354240 
DMEM for Seahorse assay Sigma D5030 
Glucose for Seahorse assay ThermoFisher A2494001 
 
Other reagents 
Reagent Supplier Cat # 
Recombinant mouse ICAM-1/CD45 Fc  R&D Systems  796-IC  
Triton X-100 Sigma T8787 
Saponin Sigma S7900 
Paraformaldehyde (PFA) Electron Microscopy Sciences 15710-S 
Glutaraldehyde Agar Scientific AGR1020 
Bovine Serum Albumin (BSA) Sigma A7906 
ProLong Diamond Antifade Mounting medium Life Technologies P36961 
Foxp3 Transcription Factor Staining Buffer Set ThermoFisher 00-5523-00 
ECL Prime Western Blotting Detection Reagent GE Healthcare RPN2232 
ATP Determination Kit ThermoFisher A22066 
CytoTox 96 Non-Radioactive Cytotoxicity Assay Promega G1780 
 
 
 
